Literature DB >> 15180142

Internal limiting membrane: ultrastructural relationships, with clinical implications for macular hole healing.

Flávio A Rezende1, Michael A Kapusta.   

Abstract

BACKGROUND: Recent data on macular hole formation have changed our understanding of the mechanisms involved. However, the mechanisms of macular hole closure, despite the introduction of internal limiting membrane (ILM) removal, are not fully understood. We reviewed the charts of patients who underwent surgery for macular hole with and without intentional removal of ILM and reviewed the basic science literature on the components and relationships of the ILM-glial cell interface to help interpret our surgical data.
METHODS: We reviewed the records of 205 eyes with a clinical diagnosis of macular hole at a university centre in Montreal between 1998 and 2002. Of these, 117 eyes of 108 patients were included. Vitrectomy with intentional ILM removal was done under indocyanine green (ICG) staining. Macular hole stage and rates of hole closure, failure and reopening were recorded, comparing the eyes with intentional ILM peeling versus no ILM peeling. Anatomic success was defined as a flat/closed configuration. A basic science literature review was done through the PubMed search engine with the key words "internal limiting membrane," "internal limiting lamina," "macular hole," "retinal glial cells" and "retinal Müller cells."
RESULTS: Eighty-four eyes had ICG-guided ILM removal (26 stage 2 macular holes, 45 stage 3 holes and 13 stage 4 holes), and 33 eyes had no ILM removal (10 stage 2 holes and 23 stage 3 holes). Of the 117 eyes 110 (94.0%) were successfully closed. Four (3.6%) of the closed holes reopened (none had ILM peeling), and 7 (6.0%) of the 117 eyes had primary failure. Ten of the 11 eyes that had primary failure or hole reopening were reoperated, and 8 were successfully closed after the second procedure. One patient refused reoperation. Including second procedures, the final anatomic closure rate was 97.4% (114/117).
INTERPRETATION: Intentional ILM peeling is not mandatory for all macular holes to close but does play a role in preventing reopening. Removal of ILM increases the rate of flat/closed hole configuration on reoperation without the need for biologic adjuvants. Review of the basic science evidence helped clarify the possible role of ILM removal.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15180142     DOI: 10.1016/s0008-4182(04)80122-4

Source DB:  PubMed          Journal:  Can J Ophthalmol        ISSN: 0008-4182            Impact factor:   1.882


  6 in total

1.  [The primary objective in macular hole surgery. Ultrastructural features of the vitreomacular interface].

Authors:  R G Schumann; M M Schaumberger; M Rohleder; C Haritoglou; A Kampik; A Gandorfer
Journal:  Ophthalmologe       Date:  2007-09       Impact factor: 1.059

2.  Re-operation of idiopathic full-thickness macular holes after initial surgery with internal limiting membrane peel.

Authors:  Mark J J D'Souza; Varun Chaudhary; Robert Devenyi; Peter J Kertes; Wai-Ching Lam
Journal:  Br J Ophthalmol       Date:  2011-02-25       Impact factor: 4.638

3.  Delayed macular hole closure.

Authors:  Peter Distelmaier; Linda M Meyer; Marie T Fischer; Sebastian Philipp; Patrick Paquet; Antje Mammen; Katharina Haller; Carl-Ludwig Schönfeld
Journal:  Case Rep Ophthalmol       Date:  2014-04-10

4.  Late Closure of a Stage III Idiopathic Macular Hole after Pars Plana Vitrectomy.

Authors:  Filiz Afrashi; Zafer Öztaş; Serhad Nalçacı
Journal:  Turk J Ophthalmol       Date:  2015-12-05

5.  Management of Stage IV Macular Holes: When Standard Surgery Fails.

Authors:  R Reis; N Ferreira; A Meireles
Journal:  Case Rep Ophthalmol       Date:  2012-08-08

6.  Evaluation of secondary surgery to enlarge the peeling of the internal limiting membrane following the failed surgery of idiopathic macular holes.

Authors:  Xin Che; Fanglin He; Linna Lu; Dongqing Zhu; Xiaofang Xu; Xin Song; Xianqun Fan; Zhiliang Wang
Journal:  Exp Ther Med       Date:  2014-01-07       Impact factor: 2.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.